[HTML] nejm.org

[HTML][HTML] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park… - … England Journal of …, 2023 - Mass Medical Soc
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …
被引用次数：55 相关文章

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

C Zhou, B Solomon, HH Loong, K Park… - The New England …, 2023 - europepmc.org
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park… - New England Journal …, 2023 - cir.nii.ac.jp
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion–Positive
NSCLC | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park, M Pérol… - THE NEW ENGLAND …, 2023 - iris.unito.it
Background: Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park… - NEW ENGLAND …, 2023 - scholarworks.bwise.kr
BackgroundSelpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

LIBRETTO-431 Trial … - New England …, 2023 - mdanderson.elsevierpure.com
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-smallcell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park… - THE NEW ENGLAND …, 2023 - cris.unibo.it
BackgroundSelpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

C Zhou, B Solomon, HH Loong… - The New England …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

C ZHOU, B SOLOMON, HH LOONG… - … England Journal of …, 2023 - observatorio.fm.usp.br
BackgroundSelpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion-positive non-small-cell lung …
[HTML] nih.gov

[HTML][HTML] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

C Zhou, B Solomon, HH Loong, K Park… - The New England …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor,
was shown to have efficacy in patients with advanced RET fusion–positive non–small-cell …